Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas.

Area of Science:

• Oncology
• Geriatrics
• Metabolism

Background:

• Sarcopenia is a known predictor of poor outcomes in various cancer patients receiving treatment.
• Skeletal muscle index (SMI) is a key metric for assessing sarcopenia.

Purpose of the Study:

• To investigate the association between sarcopenia and treatment outcomes in metastatic thyroid cancer patients receiving tyrosine kinase inhibitors (TKIs).

Main Methods:

• An observational study involving 54 metastatic thyroid cancer patients (differentiated thyroid carcinoma or medullary thyroid carcinoma) treated with TKIs.
• Patients were categorized into sarcopenia and non-sarcopenia groups based on SMI thresholds (42 cm²/m² for males, 38 cm²/m² for females).
• Retrospective review of patient records, including SMI evaluation before TKI treatment.

Main Results:

• Thirty-three patients (61%) presented with sarcopenia before TKI treatment.
• The sarcopenia group exhibited a longer duration of progression-free survival (PFS) compared to the non-sarcopenia group (median 13.6 vs. 41.9 months, p=0.017).
• Multivariate analysis identified sarcopenia as the sole independent prognostic factor for PFS (HR: 2.488, p=0.037).

Conclusions:

• Sarcopenia may serve as a predictive factor for TKI treatment outcomes in metastatic thyroid cancer.
• Targeting sarcopenia could be a potential strategy to improve prognosis in these patients.
• Further prospective studies are warranted to validate these findings.